What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
What if you could see disease coming years before symptoms appear? Chronos makes that vision a reality. Built on 100 million plasma samples from six million US donors, the platform combines real-world clinical data with high-resolution proteomics to chart molecular changes across time and populations. In this… Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More
In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More
In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More
In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. Registrations are now open for a new webinar taking place on 29 January 2026, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘. Read More
In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. Registrations are now open for a new webinar taking place on 29 January 2026, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘. Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. This webinar, hosted by DDW and supported by Evotec, will cover a diverse set of applications to illustrate how tailored and targeted proteomics fulfils scientific – and even regulatory –… Read More
